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Abstract
As a response to the 2011 National Patient Safety Goals (NPSG), a Coumadin Team,
consisting of a Physician Chair, Pharmacists, and Registered Nurses, was formed at
Mission Health System to focus on International Normalized Ratio (INR) testing,
Coumadin dosing, and patient education. The goal of this team has been to identify and
eliminate barriers that prevent the stabilization of INRs within the prescribed goal range,
and to ensure that all patients receive education about Coumadin therapy in order to
prevent harm and reduce readmission rates related to Coumadin therapy. The purpose of
this study is to compare readmission rates within the same timeframe in consecutive
years, before and after the Coumadin Team was initiated, to determine if these measures
have in fact been an effective avenue to reaching the 2011 NPSG. In a retrospective
chart review 556 patients with active Coumadin orders from July 1 – July 31, 2010 were
compared to 417 patients with active Coumadin orders from July 1 – July 31, 2011 to
determine if readmission rates in the 90 days following hospitalization were in fact lower
as a result of one-to-one Coumadin therapy education by a Registered Nurse. Research
results have confirmed that in 2010 Coumadin related readmissions occurred at a rate of
7.2% of the total patient group, while in 2011 Coumadin related readmission occurred at
a rate of 1.4% of the total patient group, giving a net reduction of Coumadin readmission
rates of 5.8% after the initiation of the Coumadin Team.
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Chapter I
Introduction
Anticoagulant therapy can be a lifesaver for many patients with health problems
ranging from atrial fibrillation, deep vein thrombosis, pulmonary embolism, and
mechanical heart valve implants to more complicated and lifelong issues with genetic
clotting disorders (U.S. Department of Veterans Affairs, 2009). Patients now have the
ability to live full and healthier lives – all while living with disease processes that would
have led to loss of life at an early age, as recently as two generations ago. Anticoagulant
therapy, like many therapies, is a blessing but also a curse, if not managed properly.
Anticoagulant medications are more likely to cause harm to patients than other therapies
because of complex dosing issues related to lifestyle, prescription and over the counter
medication interactions, and dietary restrictions (Joint Commission, 2010). Literature
reviews show that very little research has been done in this area, so research is vital if the
National Patient Safety Goals (NPSG) are going to be met. The requirements are
defined, and now the best way to meet those requirements must be determined.
Background
Originally identified in 1939, and first used on human subjects in 1941 by the
Mayo Clinic, Coumadin (warfarin) was not commonly used to treat the public until after
it was used successfully to treat President Dwight D. Eisenhower after he suffered a heart
attack in the mid-1950s (Ansell, Oertel, & Wittkowsky, 2005). Since that time,
Coumadin has become the predominant oral anticoagulant used in the United States and
North America (Ansell et al., 2005). Since those early beginnings, little else has been
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discovered about this compound. Instead, scientists have focused on the role of vitamin
K in Coumadin therapy, as well as patient education.
In 2010 the Joint Commission issued the 2011 National Patient Safety Goals and
listed among them was the need for more effective patient education related to
anticoagulant therapy. NPSG.03.05.01 specifically defines the expectations for
anticoagulant education in the following excerpt:
To achieve better patient outcomes, patient education is a vital component of an
anticoagulation therapy program. Effective anticoagulation patient education
includes face-to-face interaction with a trained professional who works closely
with patients to be sure that they understand the risks involved with
anticoagulation therapy, the precautions they need to take, and the need for
regular International Normalized Ratio (INR) monitoring. The use of
standardized practices for anticoagulation therapy that include patient
involvement can reduce the risk of adverse drug events associated with…
warfarin (NPSG).
Purpose
The purpose of this study is to determine if one-to-one education regarding
Coumadin therapy performed by a Registered Nurse can increase post-hospitalization
compliance. With a therapeutic INR goal of 2.0-3.0 and an intense therapeutic INR goal
of 2.5-3.5, it is imperative patients be compliant with their diet and laboratory testing
schedules to prevent complications from sub-therapeutic or critically high INR levels
(Barber, 2011). Completion of this study will show that one-to-one education performed
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by a Registered Nurse regarding Coumadin therapy can increase compliance and
decrease readmission rates and sentinel events related to Coumadin therapy.
Research Questions
The ultimate questions behind this research are two-fold. First, will one-to-one
Coumadin therapy education by a Registered Nurse be more relatable to the patient, and
therefore better understood? Secondly, will patients be able to put that information to
better use in relation to dietary compliance and adherence to INR testing schedules as
dictated by their primary care provider?
Hypothesis
The researcher hypothesizes this study will show that one-to-one Coumadin
therapy education performed by a Registered Nurse can increase compliance and
decrease readmission rates and sentinel events related to Coumadin therapy.
Significance
The significance of this research is evident in the fact that The Joint Commission
(TJC) is requesting interventions to reduce patient morbidity and mortality related to
anticoagulant therapy. In addition to the dangers that Coumadin therapy can present for
patients, adverse events also contribute to the increasing cost of healthcare for patients
and the institutes that serve them. Given an estimated inpatient cost of major
anticoagulant-related bleeding of $7,500, Ansell et al. (2005) report that retained annual
savings by preventing five major events would be $37,500 per 100 patients.
The National Institutes of Health Drug-Nutrient Interaction Task Force (2003)
reports the average intake of vitamin K for most adults in the U.S is 70 to 80 micrograms
(mcg) daily. The recommended daily value for vitamin K is 80 mcg, which is an estimate
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of daily need (National Institute of Health, 2003). Because vitamin K is a vital part in the
creation of functioning prothrombin, it acts as an antidote to Coumadin (Ansell et al.,
2005). It is therefore recommended that adults on Coumadin therapy limit the intake of
vitamin K rich vegetables that provide more than 60% of the daily value for vitamin K
(National Institute of Health, 2003).
The ultimate goal of this study is to ascertain whether or not one-to-one
Coumadin therapy education provided by a Registered Nurse will result in lower
readmission rates and decreased sentinel events related to Coumadin therapy. While
there is no completely accurate method of measuring compliance, Ansell et al. (2005)
report that compliance issues with Coumadin therapy are the same as other disease
processes, with the exception of the fear of bleeding. Compliance must then be measured
by the frequency of poor outcomes that are the result of non-compliance. For Coumadin
patients, poor outcomes are defined as those outcomes that lead to a major bleeding event
or a newly diagnosed clotting disorder.
Theoretical Framework
Nola Pender’s Health Promotion Model (HPM) will be used as the theoretical
framework for this study (see Figure 1). The HPM acknowledges the cognitiveperceptual factors and the modifying factors that can influence a patient’s participation in
health-promoting behaviors. Understanding patient barriers can assist the nurse in
helping the patient to understand their own perceived barriers to action and boost their
belief in their own perceived self-efficacy. Ultimately patients will be away from health
care facilities and must have a plan in effect to overcome their own barriers and to focus
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on the perceived benefits of action that will result from optimal compliance (Tomey &
Alligood, 2006).
The HPM begins by acknowledging prior related behaviors that led to less than
optimal outcomes for the patient. Personal factors for the patient that encompasses
biological, psychological, and sociocultural factors are then included as variables that
may or may not be changeable. Perceived benefits and barriers to action are then
explored with the patient to determine the most effective plan to achieve compliance
(Tomey & Alligood, 2006).
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INDIVIDUAL
CHARACTERISTICS
AND EXPERIENCES

BEHAVIOR-SPECIFIC
COGNITIONS
AND AFFECT

BEHAVIORAL
OUTCOME

Perceived benefits
of action

Prior related
behavior

Perceived barriers
to action

Immediate competing
demands (low control) and
preferences (high control)

Perceived selfefficacy

Personal
factors:
biological,
psychological
&
sociocultural

Activity-related
affect

Interpersonal
influences (family,
peers, providers),
norms, support,
models

Commitment to a
plan of action

Health-promoting
behavior

Situational
influences:
options, demand
characteristics,
aesthetics

Figure 1. Revised Health Promotion Model. (From Pender, N.J., Murdaugh, C.L. & Parsons, M.A. [2002],
Health promotion in nursing practice [4th ed., p. 60]. Upper Saddle River, NJ: Prentice-Hall.
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Table 1 and Table 2 identify how the concepts shown in the HPM will be utilized
in the educational process to increase patient knowledge regarding Coumadin therapy,
and which health promoting behaviors will be encouraged in the quest for compliance.
Table 1
Description of the Coumadin Education Plan Integrated with the HPM.
BEHAVIOR SPECIFIC COGNITIONS AND AFFECT
Perceived Benefits of Action
INR within goal range for catalyst diagnosis
Perceived Barriers of Action

Knowledge deficit related to Vitamin K
Lack of transportation for lab work

Perceived Self-Efficacy

Judgment of personal capability to limit
Vitamin K intake, find solutions to
transportation issues, and incorporate safety
precautions into lifestyle

Activity-Related Affect

Subjective feelings, be they positive or
negative surrounding the behaviors necessary
to achieve goal INR, and work within a safe
environment

Interpersonal Influences

Expectations of family or friends, level of
social support, education provided, and
modeling of other people living with
Coumadin therapy

Situational Influences

Perceptions of options available, the
demands that Coumadin therapy places on
personal lifestyle, and the aesthetic features
of the environment from which a patient
must pursue health-promoting behaviors
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Table 2
Description of Behavioral Outcomes Based on Patient Controlled Events
BEHAVIORAL OUTCOME
Immediate competing demands (low
Low Control – Timing of Coumadin
control) and preferences (high control)
administration, frequency of INR lab work,
limiting Vitamin K in diet
High Control – Diet choices with respect to
types of foods available, time of
evening/night to take Coumadin dose, where
and how INR testing takes place
Commitment to a plan of action

Plan of action should be determined with the
patient and their family (if requested), tools
to support compliance should be available
(such as dietary serving information, cost of
Coumadin and pharmacy information,
location of Coumadin clinics and style of
testing [blood draw vs. finger stick])

In this study, Pender’s concept of interpersonal influences was synonymous with
one-to-one education regarding Coumadin therapy. This education will provide the best
foundation for patients to begin to make the changes necessary to obtain all of the
benefits of anticoagulant therapy, while minimizing the risks involved. One-to-one
education would include: (a) instructions on dosing of Coumadin, (b) INR testing and
patient goals, (c) signs and symptoms of bleeding and/or blood clots, (d) tips to help
prevent cuts and bleeding, (e) possible drug interactions, (f) Coumadin storage
instructions, (g) dietary restrictions, and (h) vitamin and nutritional supplement
precautions (Mission Hospital, 2010).
Pender’s concept of perceived self-efficacy was considered to be dietary
compliance. Dietary compliance was determined by confirmation by the patient that they
have limited intake of foods high in vitamin K, limited cranberry and grapefruit juice to
eight ounces daily, eliminated liver from their diet, avoided all herbal teas, and avoided
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or limited soybeans and soy products from their diet (Mission Hospital, 2010). This
confirmation came via chart review to identify the presence of health promoting
behaviors.
Pender’s concept of health promoting behavior was considered to be the absence
of readmission within the first 90 days of hospital discharge for reasons related to
Coumadin therapy. According to Tomey and Alligood (2006), the movement to greater
responsibility and accountability for successful personal health practices requires the
support of the nursing profession through development of evidence-based practice,
(p.462). This study was performed to determine if the educational support of Registered
Nurses could influence patient responsibility and accountability and therefore reduce
readmission rates and sentinel events related to Coumadin therapy.
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Chapter II
Literature Review
The study of the effects of one-to-one patient education on Coumadin (warfarin)
self-medication by a Registered Nurse has the potential to increase patient compliance
and decrease readmission rates and sentinel events. While this study measured
readmission rates, many areas need to be evaluated to understand what these rates
represent when patients are given standard educational materials. The complexity of
Coumadin therapy requires a broad review of patient compliance as it relates to
medication dosing, INR monitoring, and dietary intake. There is simply no one factor
that often leads to an adverse event, but more of a series of factors that lead to a cascade
effect that cause the adverse event. This literature review looked at many of these areas
in an attempt to isolate the education component in understanding patient compliance.
Education and Health Literacy
A prospective, multicenter, open randomized study was performed by Pernod et
al. (2008) to evaluate the effectiveness of an oral anticoagulation patient education
program in reducing adverse events in Coumadin patients. Both hemorrhagic and
recurrent thrombotic complications were evaluated to determine the effectiveness of the
educational program. The sample included 302 patients, over the age of 18, diagnosed
with deep vein thrombosis or pulmonary emboli requiring Coumadin therapy for a
minimum of three months. Research nurses, blinded to the study groups, interviewed the
study sample 90 days after enrollment to identify episodes of bleeding and symptomatic
recurrence of venous thromboembolism (Pernod et al., 2008)
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Participants either received standard care alone, or participated in a tailored
educational intervention lasting 20-30 minutes. These educational sessions consisted of a
one-to-one teaching session. Thrombotic or hemorrhagic complications were not shown
to be decreased, as the results were similar to previous data. The significant findings of
this study were the fact that the educational intervention group did have a threefold
reduction of adverse events. The authors report that this “supports a significant and
independent impact of our educational program on the reduction in risk of events”
(Pernod et al., 2008).
Limited health literacy is but one of the factors that lead to difficulty following
medication instructions, and can often lead to poor health outcomes. Fang, Machtinger,
Wang, and Schillinger (2006) conducted a study using bivariate analysis comparisons to
determine the effect of limited health literacy on Coumadin knowledge, adherence, and
control. Medications that are known to be potentially dangerous require that patients’
understanding and participation during therapy are obtained (Fang et al., 2006).
During this study, patients were asked to complete a Test of Functional Health
Literacy in Adults (s-TOFHLA) to determine their level of health literacy, and then to
answer questions about their Coumadin therapy. One hundred seventy-nine patients
participated in this study, which ultimately determined that limited health literacy was not
associated with missing Coumadin doses, but did correlate with incorrect answers on the
mechanism of Coumadin, medication interactions, and frequency of monitoring. Limited
health literacy was not found to be associated with the percentage of time that a patient
was in therapeutic INR range (Fang et al., 2006).
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St. Louis and Robichaud-Ekstrand (2003) conducted a descriptive and
correlational study to determine if knowledge level and coping strategies correlated with
INR levels. They report that anywhere from 20 to 70% of patients are non-compliant
because of a lack of knowledge or an incorrect interpretation of physician instructions.
Interestingly, they also report that Coumadin has been found to be one of the three
medications for which geriatric patients are the least compliant. Documented reasons for
non-compliance include frequent blood tests, travel costs, diet modifications, and a belief
that the treatment is useless (St. Louis & Robichaud-Ekstrand, 2003).
This study included 100 subjects and sought to answer two questions. The first
was to identify the knowledge that older persons with atrial fibrillation had about
anticoagulant therapy and the coping strategies they used. The second was to establish
relationships between knowledge level, coping strategies, and INR levels. Researchers
found a correlation between knowledge level and coping strategies, but coping strategies
did not correlate to therapeutic INR levels (St. Louis & Robichaud-Ekstrand, 2003).
Compliance and Perceived Barriers
Parker et al. (2007) performed a prospective cohort study to assess and quantify
patient compliance of medication administration times. This study used the electronic
medication event monitoring system (MEMS) cap measurements to verify the claims of
both self-report and clinician assessment of patient adherence. One hundred forty- five
participants who were newly started on Coumadin (less than two months) were given
MEMS caps for their warfarin pill bottles, which records the time and date the bottles
were opened. Results showed that patients may benefit from adherence counseling even
when they claim to be taking their warfarin, as patient reported compliance and physician
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assessment of compliance did not often correlate with the data retrieved from the MEMS
caps. The first six months of monitoring showed worsening compliance, which was
followed by improvement beyond the six month date (Parker et al., 2007).
Woo, Chang, Ewing, and Bauer (2008) conducted research using secondary
analysis of data from a prospective cohort study to determine if Coumadin use increased
the risk of osteoporosis in older men. Medications that cause further health
complications can often result in non-compliance, as the patient may view that the risks
outweighed the benefits of that medication therapy. Bone mineral density at the hip and
spine were used as a baseline for 5533 community dwelling ambulatory men. Follow-up
at 5.1 years found that the risk of non-spine fracture was similar in warfarin user and
nonusers. Final results found that warfarin use was not associated with lower bone
mineral density, accelerated bone less, or higher non-spine fracture risk (Woo et al.,
2008).
A qualitative study using a semi-structured group interview of 11 nurses of the
Northern Sydney Area Health Service was performed by Bajorek, Krass, Ogle, Duguid,
and Shenfield (2006) to explore the barriers to Coumadin use from the nursing
perspective while working with geriatric patients. Investigators reveal that Australian
studies indicate that Coumadin therapy is underutilized in the geriatric population, even
when contraindications are absent. Lack of support services for elderly patients is cited
as one of the reasons for this underutilization (Bajorek et al., 2006).
Data from 11 nurses was collected during a group interview in order to assess the
attitudes, feelings, beliefs, experiences, and reactions that nurses had in relation to
Coumadin use. Sessions were tape recorded and notes were also taken by a scribe to
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ensure accuracy. The researchers found that nurses are a potentially underutilized
resource for prescribers and patients, which is unfortunate, as nurses maintain a unique
relationship with patients (Bajorek et al., 2006).
Safety and INR Monitoring
An open-label, three-treatment, randomized crossover clinical trial was conducted
by Mohammed Abdul et al. (2008) to determine if cranberry or garlic intake would have
a pharmacodynamic interaction with Coumadin. Intake of either cranberry or garlic
would result in patients appearing to have international normalized ratio (INR) levels that
would indicate non-compliance. A single 25mg dose of Coumadin was given to 12
healthy males alone or after two weeks of pre-treatment with either cranberry or garlic.
Both herbal medicines showed some evidence of VKORC1 genotype-dependent
interactions with warfarin, which researchers noted is worthy of further investigation
because this interaction indicates that the effects of Coumadin can be increased
significantly as a result. However, only cranberry was shown to increase the area under
the INR time curve (by 30%). Based on these results, the researchers recommended
careful monitoring of the co-administration of cranberry and warfarin (Mohammed Abdul
et al., 2008).
Lazo-Langer, Monkman, and Kovacs, (2009) performed a retrospective cohort
study of consecutive ambulatory patients treated at a thrombosis clinic in a tertiary care
hospital. The purpose of the study was to determine if a model that incorporated genetic
testing for determining warfarin dosing would be better than the nomogram currently in
use. It was thought that isolating genetic factors known to correlate with an individual’s
clotting response would enable practitioners to achieve stable maintenance doses more
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rapidly. Three hundred and sixty-three outpatients with acute venous thromboembolism
were started on treatment using a standardized Coumadin nomogram until stable, then
linear regression was used to determine if the dosing requirements would have changed if
genetic models were used. The researchers concluded that costly genetic testing was not
necessary, and that maintenance Coumadin dosing can be accurately predicted using
individual response to a standard warfarin initiation nomogram (Lazo-Langner et al.,
2009).
Researchers Rose, Ozonoff, Berlowitz, Henault, and Hylek (2009) conceded that
many factors can contribute to suboptimal INR control: non-compliance with adherence
to Coumadin therapy or dietary restrictions, interactions with other medications, and
genetic differences between patient populations. After exclusions of patients with INR
target ranges other than 2.0-3.0 and patients new to warfarin, 3961 patients were chosen
to participate in this observational study (Rose et al., 2009).
INR levels showed that a shorter follow-up interval predicted a higher likelihood
of dose change. The study also showed that a dose change in one direction at a previous
visit was predictive of a dose change in the opposite direction at the current visit. This
observational study suggests that warfarin dose changes when the INR is lower than 1.7
or higher than 3.3 could improve control, as Coumadin dose changes any closer to the 2.0
– 3.0 target range would ultimately result in a dose change in the opposite direction at the
next visit. Researchers also noted that this theory should be confirmed by a randomized
trial (Rose et al., 2009).
In order to retain the benefits of Coumadin home treatment for deep vein
thrombosis, researchers Harper, Monahan, and Baker, (2005) initiated a treatment
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program that provided 5 mg of Coumadin for the first 6 days of treatment along with INR
testing on day four and six. Standard treatment consists of using a loading dose given
over several days along with daily INR testing (Harper et al., 2005).
Using a retrospective audit after the induction of their low-dose Coumadin
loading regimen, researchers evaluated 248 patients to determine if the new protocol was
safe and effective. The new treatment protocol also included the administration of low
molecular weight heparin subcutaneously for at least five days. Coumadin was given in 5
mg doses daily with the first INR measurement taken on day four. Daily INR
measurements were then taken beginning on day six until the INR measurement reached
2.0 or higher for two consecutive measurements (Harper et al., 2005).
While this method of low dose Coumadin initiation was deemed safe by the
researchers due to the fact that of the 248 patients only eight had an INR greater than 3.0
on day four, and only one had an INR greater than 4.0 on day four; it is noted that it does
take longer for patients to reach the therapeutic level of 2.0 to 3.0. This extended time for
reaching therapeutic levels means that patients will need to take subcutaneous low
molecular weight heparin longer, as most patients required six to ten days to reach a
stable INR (Harper et al., 2005).
As more patients enter the healthcare market, researchers are trying to find ways
to meet the needs of these populations by determining if expanding the developing role of
nurses can meet those needs. Connor, Wright, and Fegan, (2002) conducted a
nonexperimental design study to determine if nurse-led anticoagulation services would be
as safe and as effective as those led by hematologists. Effectiveness was defined as
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maintaining a patient between their INR target ranges for 70% of their visits (Connor et
al., 2002).
Using a retrospective chart review, data was collected from patients who had
undergone 18 months of continuous management from the hematologist consultants
versus those who had undergone 18 months of continuous management by nurses. The
sample of patients consisted of 197 patients from 27 to 91 years of age. Results indicated
that that the anticoagulant nurses are equally as safe as the consultant hematologist in
managing the anticoagulant therapy of clinic patients (Connor et al., 2002).
This study, like the previous one, was designed to test the effectiveness of a
nurse-led anticoagulation service. What makes this one unique is that the researchers are
testing this theory in England, where patients had been traveling to their local hospital for
testing. This new service not only uses nurses, but does so in clinics that are located in
local areas or using home health nurses. The nurses are also utilizing a computer based
decision support system, which was not being used by hospital doctors (Lusignan,
Singleton, & Wells, 2004).
While patients overall liked the service because of the greater ease of testing, the
computerized decision support system proved to be challenging. Eighteen nurses
participated in this program, all of whom were experienced in anticoagulation
monitoring. The difficulty lay in situations where the computer program recommended a
particular dose and retesting date that the nurse did not agree with. Because of these
complications, nurses were reporting as never giving more Coumadin than recommended,
but they did show an increased rate of arranging follow-up dates sooner than the program
recommended. Overall, the nurses operated on the side of caution. The researchers
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concluded that while the nurses acted cautiously, technological solutions based on
hospital practice are difficult to implement in primary care (Lusignan et al., 2004).
Researchers Rose, Ozonoff, Henault, and Hylek (2008) performed a study in
order to describe the management of patients with atrial fibrillation in the community
based setting. The effectiveness of lower INR target ranges (1.5-2.5) and (2.0-2.5),
intended to prevent bleeding risk, were questioned in relation to their effectiveness of
preventing stroke. Previous studies were reported that had suggested that lower INR
levels may increase the risk of stroke without actually reducing bleeding risk. In this
community based study of 3396 patients from 101 community based practices, the
reports of hemorrhage and stroke were low, but the risk versus benefit of lower INR
ranges remains uncertain. It is interesting to note that patients who had lower INR target
ranges had more incidences of thromboembolic events and hemorrhagic events (Rose et
al., 2008).
Along with education, the second component that the Coumadin Team addresses
is the necessary follow-up that patients require upon discharge. The requirement set forth
by the team dictates that patients must have a follow-up INR check within 48-72 hours of
discharge. Research completed by Jackson, Peterson, Vial, and Jupe (2004) also
addresses this component and gives insight into the validity and efficacy of this practice.
A total of 128 patients were studied after they had been initiated on Coumadin in
the hospital. The group was randomly divided into two smaller groups, one of which
received the usual care Coumadin patients had been receiving, which consisted of not
only the usual care that their general practitioner would provide but also a visit from a
pharmacist on day eight of therapy. Their general practitioner was also contacted after
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this visit to alert them if an adverse trend was identified or if the patients INR was not in
the therapeutic range that was expected (Jackson et al., 2004).
The second group, known as the home care group, received home visits by a
pharmacist on four occasions, beginning on the second day after discharge. In addition to
earlier INR checks by this pharmacist, the patients also received education at that first
visit, consisting of information about anticoagulant therapy, possible adverse events, and
medication interactions (Jackson et al., 2004).
This study reflects an increase in positive outcomes within the home care group.
While both groups showed nearly the same percentage of patients had therapeutic INRs
at discharge, by day number eight, only 4% of the home care group proved to have a
supratherapeutic INR compared to 26% of the usual care group. In addition, when
compared at the three month mark, only 15% of the home care group had sustained a
bleeding event, while 36% of the usual care group had sustained such an event. This
study shows a marked level of improvement in patient care and safety for the home care
group (Jackson et al., 2004).
Sampling Quality
The aim of this cross-section comparison study, conducted by researchers Zengin
and Enc (2006), was to determine if concurrent blood samples taken from venipuncture
and via peripheral venous catheter showed a clinically significant difference in
prothrombin time (PT) and activated partial thromboplastin time (aPTT) in patients
currently undergoing anticoagulant therapy. While the traditional method for testing
Coumadin effectiveness is the INR, many hospitals utilize the PT/INR which does fall
under the scope of this testing (Zengin & Enc, 2006).
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A sample population was taken of 120 patients who were undergoing
anticoagulation therapy, while patients who were undergoing thrombolytic therapy were
excluded. Each type of blood sample was drawn simultaneously from the patient. Blood
collected via venipuncture was labeled as the reference sample, while blood from the
peripheral venous catheter was labeled as the experimental sample. This method allowed
each case to serve as their own control. The results of this study ultimately concluded
that it is safe practice to collect blood sample from peripheral venous catheters for use in
PT and aPTT testing (Zengin & Enc, 2006).
Throughout the literature, many areas have been studied in order to ascertain the
precise reason for adverse reactions and sentinel events related to Coumadin therapy.
The key behind all of these studies would, by all accounts, be linked to the lack of patient
knowledge regarding their therapy. This common link is evident behind the
NPSG.03.05.01 requirements as reiterated below:
To achieve better patient outcomes, patient education is a vital component of an
anticoagulation therapy program. Effective anticoagulation patient education
includes face-to-face interaction with a trained professional who works closely
with patients to be sure that they understand the risks involved with
anticoagulation therapy, the precautions they need to take, and the need for
regular International Normalized Ratio (INR) monitoring. The use of
standardized practices for anticoagulation therapy that include patient
involvement can reduce the risk of adverse drug events associated with…warfarin
(NPSG).
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The strengths of the research contained in this literature review are the various
ways that researchers are attempting to isolate the components that lead to readmissions
and sentinel events related to Coumadin therapy. Like working through a maze, the
correct path can only be discovered by revealing the failures of the other paths available.
Literature review has then outlined that genetic testing, reduced INR goals, and low dose
Coumadin initiation are not valid paths to reducing readmission rates and sentinel events
related to Coumadin therapy.
Conclusion
This literature review found many studies on the various types of barriers to
effective INR goals, however, specific studies to determine if one-to-one education by a
Registered Nurse would result in increased compliance and decreased readmission rates,
and sentinel events were scarce to non-existent. By all appearances, this is an area with a
need for research in the future.
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Chapter III
Methodology
With a therapeutic International Normalized Ratio (INR) goal of 2-3, and an
intense therapeutic INR goal of 2.5-3.5, it is imperative that patients be compliant with
their diet and laboratory testing schedules to prevent complications from sub-therapeutic
or critically high INR levels. The purpose of this research study was to ascertain whether
or not one-to-one education by a Registered Nurse about Coumadin (warfarin) therapy
could increase compliance and decrease readmission rates and sentinel events related to
Coumadin therapy (Barber, 2011).
Implementation
Quantitative data was obtained using a retrospective chart review process. Each
patient record was reviewed to determine if the patient was new to Coumadin or
continuing Coumadin therapy, what the diagnostic catalyst was for the initiation of
Coumadin therapy, and whether or not they had been readmitted to the hospital within 90
days of the research period. It was also determined if the readmissions were related or
unrelated to their Coumadin therapy. Specifically, readmissions related to Coumadin
therapy would include all cases where patients were admitted because of bleeding, and/or
cases where the patient was diagnosed with any form of a blood clot.
Setting
This research was conducted at a hospital in the Southeastern United States. This
health care facility is a designated Level II Trauma Center with over 800 inpatient beds.
Patient care units selected for this study were diverse, including Medical Surgical Units,
Progressive Care Units, Intensive Care Units, and Psychiatric Care Units. Emergency
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Care, Labor and Delivery, Pediatrics, and 24 hour observation units were not included in
the study setting.
Sample
Patient samples were obtained from the information technology department at the
health care facility. A total of 973 patients with active Coumadin orders were selected
for this study. The pre-intervention group consisted of 556 patients which were selected
from July 1, 2010 to July 31, 2010. The pre-intervention group were all patients at the
facility before the initiation of the Coumadin Team. The post-intervention group
consisted of 417 patients which were selected from July 1, 2011 to July 31, 2011. The
post-intervention group was all patients at the facility after the initiation of the Coumadin
Team. Due to the strict dietary requirements to maintain a stable INR, it was felt that
testing groups from consecutive years during the same month would eliminate variations
that could potentially exist simply because of the unavailability of some green leafy
vegetables in the other months.
All patients selected for both groups were receiving Coumadin therapy for a
history of deep vein thrombosis, pulmonary emboli, orthopedic surgery, atrial fibrillation,
atrial flutter, heart valve disease or replacement, cardiovascular disease, cerebrovascular
disease, factor V Leiden deficiencies, port-a-cath placement, or other diagnostic catalyst
as defined by their physician.
Research Design
A quasi-experimental design has been chosen to complete a retrospective chart
review for 973 patients within the selected healthcare facility. Comparisons looked at the
readmission rates of 556 Coumadin patients from July 1, 2010 to July 31, 2010, who
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were admitted before their Coumadin Team was formed, and 417 patients from July 1,
2011 to July 31, 2011, who were admitted after their Coumadin Team was formed in
January 2011. The purpose of using a quasi-experimental research design is to examine
the cause-and-effect relationship between one-to-one Coumadin education provided by a
Registered Nurse and patient compliance (Burns & Grove, 2009).
Protection of Human Subjects
Prior to conducting the chart reviews, the researcher obtained permission from the
Internal Review Board (IRB) for Gardner-Webb University in Boiling Springs, NC as
well as from the IRB for a Level II Trauma health care facility in the Southeastern United
States. As this study consisted of a retrospective chart review, informed consent was
waived by the Gardner-Webb University IRB, as well as the health care facility’s IRB.
Instruments
A data collection tool was used by the researcher to organize data obtained from
the retrospective chart review (Appendix A). This tool was designed to record the
implementation status of the patients Coumadin therapy, the diagnostic catalyst for that
therapy, and their readmission dates in the 90 days following their original admission.
The tool also recorded the number of Coumadin related readmissions, as well as the
unrelated readmissions during that same time period.
Data Collection
Data collected from the participants included their original admission date, and
whether or not they were already taking Coumadin upon admission, or were prescribed
Coumadin for the first time. Data regarding their diagnostic catalyst for Coumadin, if
they were readmitted within 90 days of the original admission, and whether or not the
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diagnosis given to them during that admission was related in any way to their Coumadin
therapy was also obtained.
Data Analysis
All data, including statistical data, was entered into the Statistical Software for the
Social Sciences, version 20 (SPSS v. 20, 2010) as well as into Microsoft Excel 2010.
From these software platforms, the researcher was able to compare the percentage of
occasions that each participant was readmitted to the hospital within the 90 day period
following their original admittance. The researcher was also able to compare the
occurrence rates of the diagnostic catalysts which prompted the physician order for
Coumadin therapy.
Summary
The need for patient education regarding Coumadin therapy is clearly needed in
order to ensure patient safety. This research project was designed to ascertain the
effectiveness of Coumadin education when provided on a one-to-one basis by a
Registered Nurse. All processes in this research project were designed to eliminate
variances that have the potential to skew the results, such as performing data collection in
the same month of the year for two consecutive years. This eliminated variations that
may occur due to the decreased availability of fresh vegetables in the winter months.
Data was also eliminated from surgeons known to prescribe Coumadin for their patients
while they were in the hospital, but discontinued it in favor of aspirin upon discharge.
The ultimate goal was to determine the effectiveness of the Coumadin Team educational
process.
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Chapter IV
Results
This research project had a clear goal. With a therapeutic International
Normalized Ratio (INR) goal of 2-3, and an intense therapeutic INR goal of 2.5-3.5, it is
imperative that patients be compliant with their diet and laboratory testing schedules to
prevent complications from sub-therapeutic or critically high INR levels. Once
completed, this study will ascertain whether or not one-to-one education by a Registered
Nurse about Coumadin (warfarin) therapy can increase compliance and decrease
readmission rates, and sentinel events related to Coumadin therapy (Barber, 2011).
Sample Characteristics
Two different samples were clearly defined in order to ascertain the effectiveness
of patient education as it relates to Coumadin therapy at the chosen healthcare facility.
The pre-intervention group was a total of 556 patients that had active Coumadin orders
between July 1 and July 31 of 2010. This sample was taken before the initiation of the
Coumadin Team. The post-intervention group was a total of 417 patients that had active
Coumadin (warfarin) orders between July 1 and July 31 of 2011. This sample was taken
after the initiation of the Coumadin Team.
The pre-intervention group from 2010 had 556 total patients; 234 patients who
were new to Coumadin therapy and 322 patients who were continuing Coumadin therapy
during their admission. The post-intervention group from 2011 had 417 total patients;
197 who were new to Coumadin therapy and 220 who were continuing Coumadin
therapy during their admission. The numbers of patients which fell in each diagnostic
category are outlined in Table 3.
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Table 3
Patient Diagnosis Rates by Year
July 1 – July 31, 2010

July 1 – July 31, 2011

107

64

111

118

210

141

41

16

21

13

15

8

0

1

1

1

0

0

1

0

Other Diagnosis requiring Coumadin
therapy

17

8

Treatment for multiple diagnoses
requiring Coumadin therapy

32

47

Treatment or secondary prevention of
venous thromboembolism or
pulmonary emboli
Prophylaxis of thromboembolism
associated with surgery or trauma
Prophylaxis of thromboembolism
associated with atrial fibrillation or
flutter
Prophylaxis of thromboembolism
associated with valvular heart disease
or prosthetic heart valves
Prophylaxis of thromboembolism
associated with heart disease
Prophylaxis of thromboembolism
associated with cerebrovascular
disease
Treatment of heparin-induced
thrombocytopenia
Diagnosis of Factor V Leiden
Protein C or S deficiency
Antiphospholipid antibody syndrome
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The last data collected during this process was the number of readmissions each
patient had in the 90 days following their initial admission within the defined dates.
Once a readmission was found, it was then researched to discover if the readmission was
related to the patient’s Coumadin therapy, or unrelated to their Coumadin therapy. The
diagnoses that were considered as related to Coumadin therapy, include any new type of
blood clot, which included but were not limited to: (a)deep vein thrombosis,
(b)pulmonary embolism, and (c) stroke due to emboli, as well as any type of bleeding
disorder, which included but were not limited to: (a)gastrointestinal bleeding and (b)
hemorrhagic stroke.
The number of readmissions related to Coumadin therapy in the 2010 group was
40, while the number of readmissions unrelated to Coumadin therapy was 135. The
number of readmissions related to Coumadin therapy in the 2011 group was 6, while the
number of readmissions unrelated to Coumadin therapy was 121. The major findings of
these results will be discussed in Chapter V. Visual representations of the sample
statistics can be found in Figures 2 through 4.
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Patient Numbers
600

556

500
417
400
322
300
200

234
197

220

2010
2011

100
0
Total number of
Total number of
Total number of
patients with active patients who were new patients who were
Coumadin orders from to Coumadin therapy continuing Coumadin
July 1st to July 31st
therapy

Figure 2. Patients Numbers by Sample Year
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Rates of Coumadin Therapy Catalyst
Diagnoses per Year
250
200
150
2010
2011

100
50
0
1

2

3

4

5

6

7

8

9

10

11

12

Figure 3. Rates of Coumadin Therapy Catalyst Diagnoses per Year
Key: (1) Deep vein thrombosis/Pulmonary emboli (2) Surgery/Trauma (3)
Atrial fibrillation (4) Valve disease/replacement (5) Cardiovascular disease
(6) Cerebrovascular disease (7) Heparin-induced thrombocytopenia (8)
Factor V Leiden (9) Protein C or S deficiency (10) Antiphospholipid
antibody syndrome (11) Other diagnoses requiring Coumadin therapy (12)
Treatment for multiple diagnoses requiring Coumadin therapy
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Readmission Rates
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20
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Figure 4. Readmission Rates per Year
Major Findings
In 2010 Coumadin related readmissions were 7.2% of the total number of
patients, while in 2011 Coumadin related readmissions were 1.4% of the total number of
patients. This represents a reduction in Coumadin related readmissions of 5.8% from
2010 (pre-intervention) to 2011 (post-intervention).
When the total number of readmissions versus the total number of patients from
the 2010 and the 2011 post-intervention group were compared, the significance in a twotailed T test showed a p value of 0.072 which when divided showed a one tail p value of
0.036, (See Table 4-6).
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Table 4
Paired Sample Statistics for the Pre and Post-Intervention Groups (Coumadin Related)

Paired Samples Statistics

Total Number of
Pair 1

Admissions

Mean

N

Std. Deviation

Std. Error Mean

486.50

2

98.288

69.500

23.00

2

24.042

17.000

Number of Coumadin
Related Readmissions

Table 5
Paired Samples Correlations for the Pre and Post-Intervention Groups (Coumadin
Related)

Paired Samples Correlations

N

Correlation

Sig.

1.000

.000

Total Number of Admissions &
Pair 1

Number of Coumadin Related
Readmissions

2
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Table 6
Paired Samples Test for the Pre and Post-Intervention Groups (Coumadin Related)

Paired Samples Test
Paired Differences
Mean

t

Std.

Std. Error

95% Confidence

Deviation

Mean

Interval of the

df

Sig. (2tailed)

Difference
Lower

Upper

-203.576

1130.576

Total Number of
Pair
1

Admissions Number of
Coumadin Related
Readmissions

463.50
0

74.246

52.500

8.829

1

.072
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The two groups were also compared for readmission unrelated to Coumadin
therapy. This two-tailed T test had a p value of 0.055, (See Table 7-9).

Table 7
Paired Sample Statistics for the Pre and Post-Intervention Groups (Coumadin Unrelated)

Paired Samples Statistics

Total Number of Admissions
Pair 1

Number of Unrelated
Admissions

Mean

N

Std. Deviation

Std. Error Mean

486.50

2

98.288

69.500

128.00

2

9.899

7.000

Table 8
Paired Samples Correlations for the Pre and Post-Intervention Groups (Coumadin
Unrelated)

Paired Samples Correlations
N

Correlation

Sig.

2

1.000

.000

Total Number of Admissions &
Pair 1

Number of Unrelated
Admissions
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Table 9
Paired Samples Test for the Pre and Post-Intervention Groups (Coumadin Unrelated)

Paired Samples Test

Paired Differences
Mean

t

Std.

Std. Error

95% Confidence

Deviation

Mean

Interval of the

df

Sig. (2tailed)

Difference
Lower

Upper

-435.638

1152.638

Total Number of
Pair
1

Admissions Number of
Unrelated

358.50
0

88.388

62.500

5.736

1

.110

Admissions

This study found a 5.8% decrease in readmission rates between the preintervention group in 2010 and the post-intervention group in 2011. It also produced a
one-tail p value of 0.036. In multivariate analysis statistical significance was obtainable
if p < 0.05.
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Chapter V
Discussion
The most important task for any new team within the hospital setting must be to
do what it set out to do, and to prove those measures are working with research and
quantifiable data. This research study was set forth to do just that. The purpose of this
research study was to look at the work being done, and ascertain whether or not
Coumadin (warfarin) therapy education by a Registered Nurse was in fact reducing
readmission rates.
Implications of Findings
In 2010 Coumadin related readmissions were 7.2% of the total number of
patients, while in 2011 Coumadin related readmissions were 1.4% of the total number of
patients. This represents a reduction in Coumadin related readmissions of 5.8% from
2010 (pre-intervention) to 2011 (post-intervention). The implications of these findings
are profound. A 5.8% reduction in the number of Coumadin related admissions in a
single month translate to more than just numbers. It translates into greater patient safety
and a reduction in health care expenditures for the individual as well as the facility.
Descriptive statistics revealed that when the total number of readmissions versus
the total number of patients from the 2010 and the 2011 post-intervention group were
compared, the significance in a two-tailed T test showed a p value of 0.072, which when
divided showed a one tail p value of 0.036. Therefore the data shows that the reduction is
statistically significant because p < 0.05, (See Tables 4-6).
The second set of descriptive statistics for the unrelated readmissions is further
proof that the decrease in readmission rates were related to the Coumadin education
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provided to patients and not because of other factors. If other factors were influencing
readmission rates, then the unrelated rates should have also proven to be statistically
significant and they were not. This two-tailed T test did not show statistical significance
as p = 0.055, which is higher than the statistically significant value of p < 0.05, (See
Tables 7-9).
As previously stated, Ansell et al., 2005) reported that the average cost for
readmission related to Coumadin therapy was $7,500, and that if one uses the average
cost, then the reduction of readmissions by five events then translated into $37,500 saved
in healthcare expenditures. This study saw a reduction in Coumadin related readmissions
of 34 events in a single month. This translates into a total savings of $255,000 in
healthcare expenditures. This benefits not only the patient, but also the healthcare
facilities which serve them.
Application to Theoretical Framework
The application to Nola Pender’s Health Promotion Model (HPM) was
appropriate for this study because it outlines the partnership that must take place between
patient and care provider to achieve an optimal outcome. Through education, the
Registered Nurse can help patients to understand which factors they can control, and
which factors they cannot control. Perceived benefits and barriers to actions can then be
explored together as a team to produce an environment with greater safety and control.
By understanding that dietary compliance and proper INR monitoring can vastly
affect their own outcomes in relation to morbidity and mortality; patients can come to
understand that they hold the key to a safe and happy future. With the proper education,
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patients then feel more equipped to handle Coumadin therapy and adjust their lifestyles to
achieve the best outcomes.
Limitations
Limitations were largely removed at the onset of this research project by careful
planning; however there was one specific limitation that was beyond the researcher’s
control. This limitation is that several patients had been prescribed Coumadin therapy,
but no clear indication could be found in the history and physical as to why. On more
than one chart, the hospitalist assigned to the patient, specifically noted in the history and
physical that neither they nor the patient knew why they were taking Coumadin.
Implications for Nursing
The implication for nursing is clear. Even if the facility, where the nurse is
employed, does not have a team dedicated to patient education about Coumadin, nurses
must find a way to ensure that patients receive Coumadin education before discharge, and
ensure that patients have a follow-up INR appointment at discharge. This research
further confirms that the 2011 NPSG are valid, and that complying with those goals does
increase patient safety.
Conclusion
In 1933, when a Wisconsin farmer named Ed Carlson brought a milk bottle full of
cows blood that would not coagulate to researchers at the University of WisconsinMadison’s Wisconsin Alumni Research Foundation (WARF) to find out why his cows
had been dying after eating spoiled sweet clover, no one could have expected that the
research that came out of this discovery would become the most widely prescribed blood
thinner in the world. Warfarin (trademarked Coumadin) took its’ name from these
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modest beginnings at WARF, and is truly a miracle drug to the thousands whose lives it
has saved (Jordan, 2011). It is not, however, a drug to be taken lightly. With frequent
lab work to be completed, and a list of dietary and other drug interactions, patients must
be presented with the best education possible so that they may pursue therapy while
minimizing the risks of the harmful and potentially fatal side effects of this medication.
One-to-one education provided by a Registered Nurse about Coumadin therapy
can increase compliance and decrease readmission rates and sentinel events related to
Coumadin therapy. Patient education must become the cornerstone of any medication
therapy regimen to provide the best outcome for our patients.
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Appendix A
Data Collection Tool
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Target period admit date:

# Coumadin related readmissions
# Non-related readmissions

This patient was initiated on therapy during this hospitalization
This patient was receiving warfarin prior to admission, and therapy is being continued
during hospitalization.

Indication for warfarin:
Treatment or secondary prevention of venousthromboembolism or pulmonary embolism
Prophylaxis of thromboembolism associated with surgery or trauma
Prophylaxis of thromboembolism associated with atrial fibrillation/flutter
Prophylaxis of thromboembolism associated with valvular heart disease or prosthetic heart valves
Prophylaxis of thromboembolism associated with cardiovascular disease
Prophylaxis of thromboembolism associated with cerebrovascular disease
Treatment of heparin-induced thrombocytopenia
Factor V Leiden
Protein C or protein S deficiency
Antiphospholipid antibody syndrome
Other:

Readmission Date:

Admit diagnosis:

Coumadin Related?

